| Today’s Big NewsJan 4, 2024 |
| By Gabrielle Masson As part of a pact with Flagship Pioneering, Novo Nordisk has inked separate cardiometabolic disease research deals with two Flagship-founded biotechs that are worth up to $532 million each. |
|
|
|
By Nick Paul Taylor Innate Pharma has begun the new year with a spring in its step, sharing news that the FDA has lifted the partial hold on lymphoma clinical trials that was imposed last year in response to the death of a patient. |
By Gabrielle Masson,Annalee Armstrong Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Annalee Armstrong Generate Biomedicines CEO Mike Nally is heading to the J.P. Morgan Healthcare Conference in San Francisco to build relationships for the AI biotech’s next partnerships. |
By Nick Paul Taylor Boehringer Ingelheim’s business development team has scorched out of the traps in 2024. Thursday, the German drugmaker unveiled its second deal of the year, revealing another T-cell anticancer therapy partnership with 3T Biosciences to swell the potential payday to $538.5 million. |
By Annalee Armstrong Bayer’s AskBio gene therapy unit has achieved a key safety milestone in an early-stage trial for an investigational Parkinson’s disease treatment that must be delivered surgically into the brain. |
By James Waldron Two days after joining the antibody-drug conjugate (ADC) race, Roche has signed another cancer-focused licensing deal. |
By Gabrielle Masson Menarini Group’s Stemline Therapeutics is paying $12 million upfront for licensing rights to Insilico Medicine’s cancer candidate in a deal potentially worth more than $500 million. |
By Max Bayer With JPM on the horizon, the dealmaking landscape is ablaze with opportunity. Avenzo, Merck KGaA and AbbVie are just the latest to sign onto new pacts. |
By Gabrielle Masson For ADC Therapeutics and Aldeyra, ringing in the new year means leaving certain programs behind in 2023. |
By Annalee Armstrong BridGene Biosciences has arrived on Galapagos island thanks to a $27 million upfront deal to develop new small molecule drugs for cancer. |
By Eric Sagonowsky After a pair of high-profile approvals for sickle cell disease gene therapies in the U.S. last month, Pfizer is ushering in the New Year with a regulatory endorsement for its hemophilia B gene therapy north of the border. |
By Joseph Keenan Velocity Clinical Research has expanded its footprint in Europe with the acquisitions of three clinical site networks in Poland and Germany. |
By Dave Muoio A state-of-the-industry report released Thursday found steady improvements in the number of organizations releasing price data, as well as the comprehensiveness and usability of those data. However, new enforcement in effect with the New Year could see noncompliant hospitals' warnings letters issued to the public. |
By Fraiser Kansteiner Investment giant Bain Capital is weighing a potential sale of its Dutch antibiotics and active pharmaceutical ingredients (API) specialist Centrient Pharmaceuticals, which could be valued as high as €1 billion ($1.09 billion), Bloomberg reported Wednesday, citing people close to the talks. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join our webinar to hear from experts on how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
Whitepaper Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
| |
|
